ArticleScientific reports2025
Optogenetic regulation of chloride ions in reactive astrocytes may mitigate Parkinson's disease pathology.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent investigations underscore the pivotal role of reactive astrocytes in the pathogenesis of Parkinson's disease (PD). As PD advances, reactive astrocytes lose their ability to degrade α-Synuclein (α-Syn) aggregates while concurrently increasing r-aminobutyric acid (GABA) secretion, which heightens inhibition of DA neurons and worsens the disease. This study explored optogenetic manipulation of reactive astrocytes as a therapeutic strategy. Halorhodopsin (NpHR), a chloride pump, was expressed in reactive astrocytes within the substantia nigra pars compacta (SNpc) of an A53T α-Syn overexpression PD rat model. Optogenetic stimulation of NpHR led to a 72.6% reduction in GABA level (p = 0.0486) and a 67.5% decrease in α-Syn aggregates (p < 0.0001) within the SNpc. Furthermore, contralateral forelimb akinesia was significantly improved by 81.4 ± 7.2% (71.6-90.9%) post-illumination in the NpHR group compared with the pre-illumination state (p = 0.0002). These results suggest that the optogenetic modulation of reactive astrocytes can alleviate astrocytic aberrant tonic inhibition of DA neurons, resulting in the revitalization of DA neurons and enhancing the degradation of α-Syn aggregates. This mechanism may ultimately ameliorate parkinsonian motor symptoms, suggesting a promising novel therapeutic avenue for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.